Practitioner's Docket No. U 013446-9

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ignacio Jose Ezquerro SAENZ, et al Serial No.: 09/831,253 Filed: June 27, 2001

Group No.: 1711

Examiner.: Ronald B. Schwadron

For: TGF BETA 1 INHIBITOR PEPTIDES

Mail Stop Sequence **Commissioner for Patents** P. O. Box 1450 Alexandria, VA 22313-1450

SUBMISSION OF "SEQUENCE LISTING," COMPUTER READABLE COPY, AND/OR AMENDMENT PERTAINING THERETO FOR BIOTECHNOLOGY INVENTION CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10*

(When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

×	deposited with the United States Postal Service in an envelope Alexandria, VA 22313-1450.	addressed to the Commissioner for Patents, P. O. Box 1450,
	37 C.F.R. 1.8(a)	37 C.F.R. 1.10*
\boxtimes	with sufficient postage as first class mail.	as "Express Man Post Office to Address" Mailing Label No (mandatory)
	TRANSMIS	
	transmitted by facsimile to the Patent and Trademark Office.	
Dat	te: <u>March 23, 2004</u>	Signature // CLIFFORD J. MASS
		(The of print name of person certifying)
*W.		thout the Express Mail mailing label thereon is an oversight care, requests for waiver of this requirement will not be

03/26/2004 FFANAEIA 00000051 09831253

01 FC:2252

210.00 GP

(Submission-Nucleotide and/or Amino Acid Sequence-page 1 of 6) 9-37

1. [X] This replies to the Office Letter DATED January 8, 2004

NOTE: If these papers are filed before the office letter issues, adequate identification of the original papers should be made, e.g., in addition to the name of the inventor and title of invention, the filing date based on the "Express Mail" procedure, the serial number from the return post card or the attorney's docket number added.

[X] A copy of the Office Letter is enclosed.

IDENTIFICATION OF PERSON MAKING STATEMENT

2. I, ____ CLIFFORD J. MASS

(type or print name of person signing below)

state the following:

ITEMS BEING SUBMITTED

3. Submitted herewith is/are

(check each item as applicable)

- A. [X] "Sequence Listing(s)" for the nucleotide and/or amino acid sequence(s) in this application. Each "Sequence Listing" is assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823.
- B. [X] An amendment to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 C.F.R. § 1.821(d).
- C. [X] A copy of each "Sequence Listing" submitted for this application in computer readable form, in accordance with the requirements of 37 C.F.R. §§ 1.821(e) and 1.824.
- D. [] Please transfer to this application, in accordance with 37 C.F.R. § 1.821(e), the computer readable copy(ies) from applicant's other application identified as follows:

NOTE: "If the computer readable form of a new application is to be identical with the computer readable form of another application of the applicant on file in the Office, reference may be made to the other application and computer readable form in lieu of filing a duplicate computer readable form in the new application. The new application shall be accompanied by a letter making such reference to the other application and computer readable form, both of which shall be completely identified." 37 C.F.R. 1.821(e).

(Submission-Nucleotide and/or Amino Acid Sequence—page 2 of 6) 9-37

In re applic Ser	eation of: rial No.:	Group No.:	
File For		Examiner:	
	uter readable form(s) of applicant's of this application or [] compare as fol	other application corresponds to the "Sequence lows:	
Computer Read	lable Form	"Sequence Identifier"	
other application	ons)	(this application)	
E. X[]	E. X[] A statement that the content of each "Sequence Listing" submitted and each compute readable copy are the same, as required in 37 C.F.R. § 1.821(f).		
[]	Because the statement is not made by the Statement is verified as required i	a person registered to practice before the Office, n 37 C.F.R. § 1.821(b).	
F. [X]	Because this submission is made in 1.821(g), a statement that the submission	n fulfilling the requirement under 37 C.F.R. § sion includes no new matter.	
[]	Because the statement is not made by	a person registered to practice before the Office,	

STATEMENT THAT "SEQUENCE LISTING" AND COMPUTER READABLE COPY ARE THE SAME AND/OR THAT PAPERS SUBMITTED INCLUDES NO NEW MATTER

4. I hereby state:

(complete applicable item A and/or B)

- A. [X] Each computer readable form submitted in this application, including those forms requested to be transferred from applicant's other application, is the same as the "Sequence Listing" to which it is indicated to relate.
- B. [X] All papers accompanying this submission, or for which a request for transfer from applicants' other application, introduce no new matter.

STATUS

5.	Applicant is		
	[X] a small entity. A statement: [] is attached.		
	[X] was already filed.		

[] other than a small entity.

EXTENSION OF TERM

6.

NOTE: 37 C.F.R. § 1.704(b)"... an applicant shall be deemed to have failed to engage in reasonable efforts to conclude processing or examination of an application for the cumulative total of any periods of time in excess of three months that are taken to reply to any notice or action by the Office making any rejection, objection, argument, or other request, measuring such three-month period from the date the notice or action was mailed or given to the applicant, in which case the period of adjustment set forth in § 1.703 shall be reduced by the number of days, if any, beginning on the day after the date that is three months after the date of mailing or transmission of the Office communication notifying the applicant of the rejection, objection, argument, or other request and ending on the date the reply was filed. The period, or shortened statutory period, for reply that is set in the Office action or notice has no effect on the three-month period set forth in this paragraph."

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry of a Notice of Appeal or filing and/or entry of an additional amendment after expiration of the shortened statutory period unless the timely-filed response placed the application in condition for allowance. Of course, if a Notice of Appeal has been filed within the shortened statutory period, the period has ceased to run." Notice of Dec. 10, 1985 (1061 O.G. 34-35).

- NOTE: See 37 C.F.R. 1.645 for extensions of time in interference proceedings and 37 C.F.R. 1.550(c) for extensions of time in reexamination proceedings.
- 7. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply.

(complete (a) or (b) as applicable).

(a) [x] Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(4)) for the total number of months checked below:

	Extension (months)	Fee for other than small entity	Fee for small entity
[]	one month	\$110.00	\$ 55.00
[x]	two months	\$420.00	\$ 210.00
[]	three months	\$950.00	\$ 475.00
ΪĨ	four months	\$1,480.00	\$ 740.00

Fee \$ 210

If an additional extension of time is required, please consider this a petition therefor.

(check and complete the next item, if applicable) [] An extension for _____ months has already been secured, and the fee paid therefor of \$ ____ is deducted from the total fee due for the total months of extension now requested. Extension fee due with this request \$ _____ OR (b) [] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition and fee for extension of time. FEE PAYMENT 8. [x] Attached is a check in the sum of \$ _____. A duplicate of this transmittal is attached.

FEE DEFICIENCY

9.

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, 1065 O.G. 31-33.

10. [X] If any additional extension and/or fee is required, charge Account No. 12-0425.

(Submission-Nucleotide and/or Amino Acid Sequence—page 5 of 6) 9-37

	(type or print name of person signing statement) Signature
March 23, 2004	Signature
Date	
c/o Ladas & Parry P.O. Address of Signatory	4/
26 West 61st Street New York, N.Y. 10023	
(If applicable)	[] Inventor[] Assignee of complete interest[] Person authorized to sign on behalf of assignee
Tel. No.: (212) 708-1890	[X] Practitioner of record
Reg. No. 30,086	 [] Filed under Rule 34(a) [] Registration No [] Other (specify identity of person signing)
(complete the f	collowing, if applicable)
(type name of assignee)	
Address of assignee	
Title of person authorized to sign on behalf of assignee	
A "STATEMENT UNDER 37 C.F.R. 3.73(b)"	is attached.
Assignment recorded in PTO on Reel Frame	
	SIGNATURE OF PRACTITIONER
Reg. No.	(type or print name of practitioner)
Tel. No.: ()	P.O. Address
Customer No.:	
	c/o Ladas & Parry 26 West 61 st Street New York, N.Y. 10023

(Submission-Nucleotide and/or Amino Acid Sequence—page 6 of 6) 9-37

SIGNATURE(s)



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ignacio Jose Ezquerro SAENZ, et al Serial No.: 09/831,253 Group No.: 1711

Filed: June 27, 2001 Examiner.: Ronald B. Schwadron

For: TGF BETA 1 INHIBITOR PEPTIDES

Attorney Docket No.: U 013446-9

Commissioner for Patents Washington, D.C. 20231

AMENDMENT

In response to the Official Communication of January 8, 2004, please amend the application as follows:

CERTIFICATION UNDER 37 C.F.R. 1.8(a) and 1.10* (When using Express Mail, the Express Mail label number is mandatory; Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. 1.8(a)

37 C.F.R. 1.10*

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Date: March 23, 2004

Signature

CLIFFORD J. MASS
(type or print name of person certifying)

*WARNING:

Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. 1.10(b).

"Since the filing of correspondence under § 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed.

Reg. 56,439, at 56,442.